References
- Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271–281.
- Zaucha JM, Wyrowinska E, Prejzner W, . Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. Clin Lab Haematol 2006;28:208–210.
- Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 2005;46:781–784.
- Khan KA, Junaid A, Siddiqui NS, . Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia. J Coll Physicians Surg Pak 2008;18:176–178.
- Sumi M, Tauchi T, Shimamoto T, . Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy. Rinsho Ketsueki 2002;43:868–870.
- Petzer AL, Eaves CJ, Barnett MJ, . Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997;90:64–69.
- Su RJ, Zhang XB, Li K, . Platelet-derived growth factor promotes ex vivo expansion of CD34 + cells from human cord blood and enhances long-term culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells. Br J Haematol 2002;117:735–746.
- Demetri GD, Von Mehren M, Blanke CD, . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–480.
- Brummendorf TH, Dragowska W, Zijlmans JM, . Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells. J Exp Med 1998;188:1117–1124.
- Bartolovic K, Balabanov S, Hartmann U, . Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004;103: 523–529.
- Fang G, Kim CN, Perkins CL, . CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000;96:2246–2253.
- Hoepfl J, Miething C, Grundler R, . Effects of imatinib on bone marrow engraftment in syngeneic mice. Leukemia 2002;16: 1584–1588.
- Pirson L, Baron F, Giet O, . Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor STI571 does not impair engraftment of human CD34 + cells into NOD/SCIDb2mnull mice. Blood 2002;100(Suppl. 1): Abstract.
- Graham SM, Jorgensen HG, Allan E, . Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319–325.
- Holtz MS, Slovak ML, Zhang F, . Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792–3800.
- Dewar AL, Domaschenz RM, Doherty KV, . Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003;17:1713–1721.
- Seymour JF, Grigg A, Reynolds A, . Imatinib’s potential effects on fertility, immunity and pulmonary function: a prospective study in patients with previously untreated CML. Blood 2004;104(Suppl. 1): Abstract 1020.
- Sneed TB, Kantarjian HM, Talpaz M, . The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116–121.
- Srinivas U, Pillai LS, Kumar R, . Bone marrow aplasia—a rare complication of imatinib therapy in CML patients. Am J Hematol 2007;82:314–316.